Lexicon Pharmaceuticals, Inc. (LXRX): Price and Financial Metrics

LXRX POWR Grades

• LXRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 28.06% of US stocks.
• The strongest trend for LXRX is in Growth, which has been heading down over the past 177 days.
• LXRX's current lowest rank is in the Quality metric (where it is better than 2.18% of US stocks).

LXRX Stock Summary

• With a price/sales ratio of 465.86, LEXICON PHARMACEUTICALS INC has a higher such ratio than 99.15% of stocks in our set.
• With a year-over-year growth in debt of 340.25%, LEXICON PHARMACEUTICALS INC's debt growth rate surpasses 96.89% of about US stocks.
• Revenue growth over the past 12 months for LEXICON PHARMACEUTICALS INC comes in at 324.8%, a number that bests 97.98% of the US stocks we're tracking.
• Stocks with similar financial metrics, market capitalization, and price volatility to LEXICON PHARMACEUTICALS INC are DZSI, TBIO, TARS, URGN, and SONO.
• LXRX's SEC filings can be seen here. And to visit LEXICON PHARMACEUTICALS INC's official web site, go to www.lexpharma.com.

LXRX Valuation Summary

• In comparison to the median Healthcare stock, LXRX's EV/EBIT ratio is 129.44% lower, now standing at -2.9.
• LXRX's EV/EBIT ratio has moved up 0.3 over the prior 243 months.

Below are key valuation metrics over time for LXRX.

LXRX Growth Metrics

Its 3 year revenue growth rate is now at -99.35%.
• Its 5 year net cashflow from operations growth rate is now at 153.99%.
• The year over year cash and equivalents growth rate now stands at -39.05%.

LXRX's revenue has moved down $321,948,000 over the prior 33 months.

The table below shows LXRX's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	0.125	-90.11	-97.061
2022-06-30	0.109	-87.821	-96.796
2022-03-31	0.308	-85.279	-90.276
2021-12-31	0.298	-87.017	-87.758
2021-09-30	0.483	-98.428	-67.642
2021-06-30	7.094	-121.656	38.083

LXRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• LXRX has a Quality Grade of D, ranking ahead of 14.8% of graded US stocks.
• LXRX's asset turnover comes in at 0.038 -- ranking 340th of 681 Pharmaceutical Products stocks.
• SEEL, AVEO, and OTLK are the stocks whose asset turnover ratios are most correlated with LXRX.

The table below shows LXRX's key quality metrics over time.